Last reviewed · How we verify
Epilim — Competitive Intelligence Brief
marketed
Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2
Neuroscience
Live · refreshed every 30 min
Target snapshot
Epilim (sodium valproate) — Sanofi.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Epilim TARGET | sodium valproate | Sanofi | marketed | Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Epilim — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium valproate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing